Julie Zhen Qin Wu

Array ( [id] => 9120841 [patent_doc_number] => 20130287763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR' [patent_app_type] => utility [patent_app_number] => 13/812249 [patent_app_country] => US [patent_app_date] => 2011-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 27537 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13812249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7742257 [patent_doc_number] => 20120020961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 13/189403 [patent_app_country] => US [patent_app_date] => 2011-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 59 [patent_no_of_words] => 25127 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20120020961.pdf [firstpage_image] =>[orig_patent_app_number] => 13189403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147886 [patent_doc_number] => 20130302409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 13/810548 [patent_app_country] => US [patent_app_date] => 2011-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12503 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13810548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8707571 [patent_doc_number] => 20130064860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'Combination pharmaceutical composition and methods of theating genitourinary system disorders' [patent_app_type] => utility [patent_app_number] => 13/135898 [patent_app_country] => US [patent_app_date] => 2011-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13452 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13135898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8854278 [patent_doc_number] => 20130143954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'RECOMBINANT VECTOR FOR SUPPRESSING PROLIFERATION OF HUMAN PAPILLOMA VIRUS CELLS INCLUDING ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 1 (PITUITARY) GENE AND PHARMACEUTICAL COMPOSITION FOR TREATING HUMAN PAPILLOMA VIRUS' [patent_app_type] => utility [patent_app_number] => 13/806666 [patent_app_country] => US [patent_app_date] => 2011-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7623 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13806666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9951343 [patent_doc_number] => 09000130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Cysteine engineered antibodies and conjugates' [patent_app_type] => utility [patent_app_number] => 13/154672 [patent_app_country] => US [patent_app_date] => 2011-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 31962 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13154672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11809734 [patent_doc_number] => 09714294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-25 [patent_title] => 'Monoclonal antibodies against HER2 epitope' [patent_app_type] => utility [patent_app_number] => 13/700246 [patent_app_country] => US [patent_app_date] => 2011-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 30627 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13700246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106299 [patent_doc_number] => 09862769 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibodies against HER2' [patent_app_type] => utility [patent_app_number] => 13/700341 [patent_app_country] => US [patent_app_date] => 2011-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 42 [patent_no_of_words] => 45127 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 502 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13700341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7586290 [patent_doc_number] => 20110280800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-17 [patent_title] => 'IL-1 BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/107439 [patent_app_country] => US [patent_app_date] => 2011-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 92101 [patent_no_of_claims] => 122 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0280/20110280800.pdf [firstpage_image] =>[orig_patent_app_number] => 13107439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8920471 [patent_doc_number] => 08486402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-16 [patent_title] => 'Anti-CD98 antibody' [patent_app_type] => utility [patent_app_number] => 13/106280 [patent_app_country] => US [patent_app_date] => 2011-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20943 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13106280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8853624 [patent_doc_number] => 20130143299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'RNF8-FHA DOMAIN-MODIFIED PROTEIN AND METHOD OF PRODUCING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/810025 [patent_app_country] => US [patent_app_date] => 2011-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9676 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13810025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989195 [patent_doc_number] => 20130216476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'USE OF AN ANTI-CD71 ANTIBODY FOR PREPARING A MEDICAMENT' [patent_app_type] => utility [patent_app_number] => 13/696097 [patent_app_country] => US [patent_app_date] => 2011-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9409 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13696097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8884777 [patent_doc_number] => 20130157961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/695390 [patent_app_country] => US [patent_app_date] => 2011-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26100 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13695390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8822147 [patent_doc_number] => 20130123192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'COMPOSITIONS AND METHODS FOR INHIBITING MATRIX METALLOPROTEINASE (MMP)-MEDIATED CELL MIGRATION' [patent_app_type] => utility [patent_app_number] => 13/642078 [patent_app_country] => US [patent_app_date] => 2011-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 28535 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13642078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7579629 [patent_doc_number] => 20110293512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-01 [patent_title] => 'Compositions and Methods for Inhibiting Growth of SMAD-4 Deficient Cancers' [patent_app_type] => utility [patent_app_number] => 13/088774 [patent_app_country] => US [patent_app_date] => 2011-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 26203 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0293/20110293512.pdf [firstpage_image] =>[orig_patent_app_number] => 13088774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7734308 [patent_doc_number] => 20120016340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-19 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER' [patent_app_type] => utility [patent_app_number] => 13/088159 [patent_app_country] => US [patent_app_date] => 2011-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 88147 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0016/20120016340.pdf [firstpage_image] =>[orig_patent_app_number] => 13088159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11611536 [patent_doc_number] => 09649378 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Cancer methods' [patent_app_type] => utility [patent_app_number] => 13/639643 [patent_app_country] => US [patent_app_date] => 2011-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 22 [patent_no_of_words] => 39740 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13639643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8637087 [patent_doc_number] => 20130028891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 13/639172 [patent_app_country] => US [patent_app_date] => 2011-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6572 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13639172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8853109 [patent_doc_number] => 20130142784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'METHOD OF TREATING TUMOR RESISTANT TO HERCEPTIN OR PACLITAXEL USING FOXM1 INHIBITORS AND DETECTING SAME' [patent_app_type] => utility [patent_app_number] => 13/640245 [patent_app_country] => US [patent_app_date] => 2011-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20884 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13640245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828685 [patent_doc_number] => 20130129730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/638223 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 37221 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13638223 [rel_patent_id] =>[rel_patent_doc_number] =>)